La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Bavarian Nordic Gestion

Gestion contrôle des critères 0/4

Informations clés

Paul Chaplin

Directeur général

DKK 23.4m

Rémunération totale

Pourcentage du salaire du PDG	30.7%
Durée du mandat du directeur général	10.2yrs
Propriété du PDG	0.1%
Durée moyenne d'occupation des postes de direction	4.6yrs
Durée moyenne du mandat des membres du conseil d'administration	3.6yrs

Mises à jour récentes de la gestion

Recent updates

Bavarian Nordic (CPH:BAVA) Seems To Use Debt Quite Sensibly

Aug 09

Bavarian Nordic A/S' (CPH:BAVA) Shareholders Might Be Looking For Exit

Jul 11

Results: Bavarian Nordic A/S Delivered A Surprise Loss And Now Analysts Have New Forecasts

May 12

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Apr 09

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Feb 26

Bavarian Nordic A/S' (CPH:BAVA) Business And Shares Still Trailing The Industry

Jan 03

Bavarian Nordic A/S (CPH:BAVA) Shares Could Be 45% Below Their Intrinsic Value Estimate

Dec 10

Here's Why Bavarian Nordic (CPH:BAVA) Can Manage Its Debt Responsibly

Nov 15

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Aug 17

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Apr 19

Is Bavarian Nordic (CPH:BAVA) Weighed On By Its Debt Load?

Jan 03

Bavarian Nordic (CPH:BAVA) Has Debt But No Earnings; Should You Worry?

Sep 15

Rainbows and Unicorns: Bavarian Nordic A/S (CPH:BAVA) Analysts Just Became A Lot More Optimistic

Jul 24

Industry Analysts Just Made A Notable Upgrade To Their Bavarian Nordic A/S (CPH:BAVA) Revenue Forecasts

Jun 14

Analyst Forecasts Just Became More Bearish On Bavarian Nordic A/S (CPH:BAVA)

May 31

Is Bavarian Nordic (CPH:BAVA) Using Debt In A Risky Way?

May 06

Analyse de la rémunération des PDG

Comment la rémunération de Paul Chaplin a-t-elle évolué par rapport aux bénéfices de Bavarian Nordic?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Mar 31 2024	n/a	n/a	DKK 984m
Dec 31 2023	DKK 23m	DKK 7m	DKK 1b
Sep 30 2023	n/a	n/a	DKK 723m
Jun 30 2023	n/a	n/a	DKK 1b
Mar 31 2023	n/a	n/a	DKK 301m
Dec 31 2022	DKK 22m	DKK 6m	-DKK 347m
Sep 30 2022	n/a	n/a	-DKK 599m
Jun 30 2022	n/a	n/a	-DKK 693m
Mar 31 2022	n/a	n/a	-DKK 606m
Dec 31 2021	DKK 18m	DKK 6m	-DKK 465m
Sep 30 2021	n/a	n/a	-DKK 737m
Jun 30 2021	n/a	n/a	-DKK 629m
Mar 31 2021	n/a	n/a	-DKK 368m
Dec 31 2020	DKK 14m	DKK 5m	DKK 278m
Sep 30 2020	n/a	n/a	DKK 606m
Jun 30 2020	n/a	n/a	DKK 481m
Mar 31 2020	n/a	n/a	DKK 267m
Dec 31 2019	DKK 12m	DKK 5m	-DKK 347m
Sep 30 2019	n/a	n/a	-DKK 402m
Jun 30 2019	n/a	n/a	-DKK 271m
Mar 31 2019	n/a	n/a	-DKK 279m
Dec 31 2018	DKK 12m	DKK 6m	-DKK 362m
Sep 30 2018	n/a	n/a	-DKK 445m
Jun 30 2018	n/a	n/a	-DKK 151m
Mar 31 2018	n/a	n/a	DKK 5m
Dec 31 2017	DKK 13m	DKK 5m	DKK 181m

PDG

Paul Chaplin (57 yo)

10.2yrs

Titularisation

DKK 23,428,000

Compensation

Dr. Paul John Chaplin, M.Sc., Ph D., has been the Chief Executive Officer and President at Bavarian Nordic A/S since May 28, 2014. Dr. Chaplin served as an Executive Vice President of Bavarian Nordic A/S f...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Paul Chaplin	CEO & President	10.2yrs	DKK 23.43m	0.11% DKK 22.6m
Henrik Juuel	CFO & Executive VP	5.8yrs	DKK 12.23m	pas de données
Russell Thirsk	Executive VP & COO	2.3yrs	pas de données	pas de données
Rolf Sørensen	Vice President of Investor Relations & Communications	no data	pas de données	pas de données
Anu Kerns	Executive VP and Chief People & Sustainability Officer	3.8yrs	pas de données	pas de données
Jean-Christophe May	Executive VP & Chief Commercial Officer	4.6yrs	pas de données	pas de données

4.6yrs

Durée moyenne de l'emploi

57yo

Âge moyen

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Peter Kürstein-Jensen	Independent Director	12.3yrs	DKK 740.00k	0.026% DKK 5.5m
Anders Pedersen	Deputy Chairman	14.3yrs	DKK 1.13m	0.024% DKK 5.1m
Franciscus A. G. Verwiel	Independent Director	8.3yrs	DKK 830.00k	0.0055% DKK 1.2m
Anne Eberhard	Independent Director	5.3yrs	DKK 860.00k	0.0035% DKK 725.0k
Luc Debruyne	Independent Chairman	1.4yrs	DKK 1.43m	pas de données
Heidi Hunter	Independent Director	1.6yrs	DKK 635.00k	pas de données
Linette Munksgaard Andersen	Employee-Elected Member of the Board	3.6yrs	DKK 475.00k	0.00070% DKK 145.8k
Thomas Alex Bennekov	Employee-Elected Member of the Board	3.6yrs	DKK 475.00k	0.0024% DKK 497.9k
Anja Gjol	Employee-Elected Member of the Board	3.6yrs	DKK 475.00k	0.00070% DKK 145.8k
Karen Merete Jensen	Employee-Elected Member of the Board	3.6yrs	DKK 475.00k	0.00088% DKK 183.3k
Johan Hoof	Independent Director	1.6yrs	DKK 575.00k	pas de données
Montse Picart	Independent Director	less than a year	pas de données	pas de données

3.6yrs

Durée moyenne de l'emploi

62yo

Bavarian Nordic Gestion

Gestion contrôle des critères 0/4

Informations clés

Mises à jour récentes de la gestion

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

Deputy Chairman exercised options to buy kr.123k worth of stock.

CEO & President exercised options to buy kr.1.4m worth of stock.

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

Chairman recently sold kr.508k worth of stock

Less than half of directors are independent

Recent updates

New major risk - Share price stability

Bavarian Nordic A/S Submits Data to EMA to Extend Mpox/Smallpox Vaccine Approval to Adolescents

Investor sentiment improves as stock rises 18%

Bavarian Nordic (CPH:BAVA) Seems To Use Debt Quite Sensibly

Bavarian Nordic A/S Receives Positive Chmp Opinion for Including Mpox Real-World Effectiveness Data in European Marketing Authorization for Smallpox and Mpox Vaccine

Bavarian Nordic A/S Receives EMA Filing Acceptance and Validation of the MAA for Its Chikungunya Vaccine

Bavarian Nordic A/S' (CPH:BAVA) Shareholders Might Be Looking For Exit

Bavarian Nordic A/S Submits Marketing Authorization Application for Its Chikungunya Vaccine Candidate to Ema

Investor sentiment improves as stock rises 18%

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

Results: Bavarian Nordic A/S Delivered A Surprise Loss And Now Analysts Have New Forecasts

First quarter 2024 earnings released: kr.1.50 loss per share (vs kr.5.10 profit in 1Q 2023)

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Deputy Chairman exercised options to buy kr.123k worth of stock.

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

CEO & President exercised options to buy kr.1.4m worth of stock.

Full year 2023 earnings released: EPS: kr.19.20 (vs kr.4.93 loss in FY 2022)

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

Price target increased by 9.4% to kr.293

Bavarian Nordic A/S' (CPH:BAVA) Business And Shares Still Trailing The Industry

Bavarian Nordic A/S (CPH:BAVA) Shares Could Be 45% Below Their Intrinsic Value Estimate

Third quarter 2023 earnings released: kr.4.40 loss per share (vs kr.0.20 profit in 3Q 2022)

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Here's Why Bavarian Nordic (CPH:BAVA) Can Manage Its Debt Responsibly

Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

Investor sentiment improves as stock rises 15%

Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Bavarian Nordic A/S Provides Update on RSV Vaccine Program

Investor sentiment deteriorates as stock falls 26%

Bavarian Nordic A/S Reports Data from A Phase 3 Clinical Trial of Its Vlp-Based Chikungunya Virus Vaccine in Adults >=65 Years of Age Study Successfully Met Its Primary Endpoints

Bavarian Nordic A/S Reports 12-Month Durability Data from Phase 2 Clinical Trial of Covid-19 Vaccine Candidate

Consensus EPS estimates increase by 40%

Bavarian Nordic A/S acquired Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $384 million.

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Full year 2022 earnings released: kr.4.90 loss per share (vs kr.7.37 loss in FY 2021)

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S Provides Earnings Guidance for Fiscal Year 2023

Bavarian Nordic A/S Provides Revenue Guidance for Fiscal Year 2022

Is Bavarian Nordic (CPH:BAVA) Weighed On By Its Debt Load?

Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults

Chairman recently sold kr.508k worth of stock

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: kr.0.20 (vs kr.1.30 loss in 3Q 2021)

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic A/S Announces Covid-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial

Bavarian Nordic A/S Appoints Luc Debruyne as Board of Directors

Bavarian Nordic (CPH:BAVA) Has Debt But No Earnings; Should You Worry?

Bavarian Nordic A/S Revises Earnings Guidance for the Full Year 2022

Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate

Bavarian Nordic A/S, Annual General Meeting, Mar 30, 2023

Bavarian Nordic A/S to Report Fiscal Year 2022 Final Results on Mar 02, 2023

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to kr.418

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2022

Consensus forecasts updated

Bavarian Nordic A/S Receives U.S. and Eu Approvals of Its Fill and Finish Vaccine Manufacturing Facility

Price target increased to kr.390

Rainbows and Unicorns: Bavarian Nordic A/S (CPH:BAVA) Analysts Just Became A Lot More Optimistic

Bavarian Nordic A/S Receives Positive CHMP Opinion on the Extension of Vaccine Label to Include Monkeypox

Consensus estimates of losses per share improve by 21%